Background: Among all the treatment methods developed so far, opioid agonist treatment (OAT) is the most effective therapy for opioid dependence. While methadone (MTD) is the most commonly used, fewer data are available on alternative opioid agonist. The aim of this study was to assess the efficacy of buprenorphine (BUP) and slow-released morphine compared to MTD with regard to the reduction of concomitant heroin and cocaine use. Methods: This cross-sectional study included 105 patients receiving MTD, BUP, or slow-release morphine as opioid agonist therapy at the Psychiatric Hospital of Zurich. Illicit drug use was assessed using a retrospective 3-month hair toxicology analysis to quantify concentrations of heroin degradation products and metabolites, as well as cocaine and cocaine metabolites. We have also collected self-reports, but in the data of the study, only the results of the hair analysis were considered. Results: BUP-treated patients showed lower rates of illicit opiate consumption in comparison to the group treated with MTD or slow-released morphine (p < 0.05). The proportion of heroin-positive hair samples associated with slow-release morphine treatment was similar to the proportion associated with MTD treatment. Neither the MTD vs. slow-released morphine groups nor the BUP vs. MTD groups showed significant differences in the number of patients consuming cocaine although patients in the BUP group had significantly lower concentrations of cocaine in hair testing compared to the patients in the MTD group. Prevalence of cocaine consumption was also significantly lower in the BUP group compared to patients in the slow-release morphine group (p < 0.05). Conclusion: This study suggests that BUP OAT is associated with reduced additional opiate co-use.

1.
Organization WH. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. 2009.
2.
Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.
Cochrane Database Syst Rev
. 2011 Oct;(10):CD004147.
3.
Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence.
Lancet
. 1999 Jan;353(9148):221–6.
4.
Bravo MJ, Llorens N, Barrio G, Brugal MT, Santos S, Sordo L, et al.; Itinere Project Group. Methadone maintenance treatment: a protective factor for cocaine injection in a street-recruited cohort of heroin users.
Drug Alcohol Depend
. 2010 Nov;112(1–2):62–8.
5.
Herdener M, Dürsteler KM, Seifritz E, Nordt C. Changes in substance use in patients receiving opioid substitution therapy and resulting clinical challenges: a 17-year treatment case register analysis.
Lancet Psychiatry
. 2017 Apr;4(4):302–9.
6.
Eurosurveillance editorial team. The European Monitoring Centre for Drugs and Drug Addiction publishes the European Drug Report 2013: trends and developments.
Euro Surveill
. 2013 May;18(22):20491.
7.
Besson J, Beck T, Wiesbeck G, Hämmig R, Kuntz A, Abid S, et al. Opioid maintenance therapy in Switzerland: an overview of the Swiss IMPROVE study.
Swiss Med Wkly
. 2014 Mar;144:w13933.
8.
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.
Cochrane Database Syst Rev
. 2009 Jul;(3):CD002209.
9.
Kastelic A, Dubajic G, Strbad E. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression.
Addiction
. 2008 Nov;103(11):1837–46.
10.
Kreek MJ. Medical safety and side effects of methadone in tolerant individuals.
J Psychoactive Drugs
. 1991;23(2):6 pages following 232.
11.
Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.
Clin Pharmacokinet
. 2005;44(7):661–80.
12.
Amass L, Bickel WK, Crean JP, Blake J, Higgins ST. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans.
Psychopharmacology (Berl)
. 1998 Apr;136(3):217–25.
13.
Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stühlinger G, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence.
Addiction
. 1999 Sep;94(9):1337–47.
14.
Giacomuzzi SM, Riemer Y, Ertl M, Kemmler G, Rössler H, Hinterhuber H, et al. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment.
Addiction
. 2003 May;98(5):693–702.
15.
Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence.
Clin Pharmacol Ther
. 2004 Jan;75(1):34–48.
16.
Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome.
Drug Alcohol Depend
. 2004 Jul;75(1):37–45.
17.
Eder H, Jagsch R, Kraigher D, Primorac A, Ebner N, Fischer G. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy.
Addiction
. 2005 Aug;100(8):1101–9.
18.
Hämmig R, Köhler W, Bonorden-Kleij K, Weber B, Lebentrau K, Berthel T, et al. Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence.
J Subst Abuse Treat
. 2014 Oct;47(4):275–81.
19.
Jegu J, Gallini A, Soler P, Montastruc JL, Lapeyre-Mestre M. Slow-release oral morphine for opioid maintenance treatment: a systematic review.
Br J Clin Pharmacol
. 2011 Jun;71(6):832–43.
20.
Beck T, Haasen C, Verthein U, Walcher S, Schuler C, Backmund M, et al. Maintenance treatment for opioid dependence with ­slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone.
Addiction
. 2014 Apr;109(4):617–26.
21.
Mutschler J, Gastberger S, Baumgartner MR, Grosshans M, Seifritz E, Quednow BB, et al. Pregabalin Use Among Opioid-Addicted Patients in Switzerland.
J Clin Psychiatry
. 2016 Sep;77(9):1202–3.
22.
Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T, et al. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.
Addiction
. 2019 Jan;114(1):103–11.
23.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression.
Arch Gen Psychiatry
. 1961 Jun;4(6):561–71.
24.
Spielberger CD, Gorsuch R.
L., Lushene, R., Vagg, P. R., &amp; Jacobs, G. A. Manual for the State-Trait Anxiety Inventory
. Palo Alto (CA): Consulting Psychologists Press; 1983.
25.
Rosenberg H. Clinical and laboratory assessment of the subjective experience of drug craving.
Clin Psychol Rev
. 2009 Aug;29(6):519–34.
26.
Madry MM, Bosshard MM, Kraemer T, Baumgartner MR. Hair analysis for opiates: hydromorphone and hydrocodone as indicators of heroin use.
Bioanalysis
. 2016 May;8(9):953–64.
27.
Pötsch L, Skopp G. Stability of opiates in hair fibers after exposure to cosmetic treatment.
Forensic Sci Int
. 1996 Aug;81(2–3):95–102.
28.
Rust KY, Baumgartner MR, Meggiolaro N, Kraemer T. Detection and validated quantification of 21 benzodiazepines and 3 “z-drugs” in human hair by LC-MS/MS.
Forensic Sci Int
. 2012 Feb;215(1–3):64–72.
29.
Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse.
Clin Chim Acta
. 2006 Aug;370(1–2):17–49.
30.
Hegstad S, Khiabani HZ, Kristoffersen L, Kunøe N, Lobmaier PP, Christophersen AS. Drug screening of hair by liquid chromatography-tandem mass spectrometry.
J Anal Toxicol
. 2008 Jun;32(5):364–72.
31.
McCance-Katz EF, Jatlow P, Rainey PM. Effect of cocaine use on methadone pharmacokinetics in humans.
Am J Addict
. 2010 Jan-Feb;19(1):47–52.
32.
Petitjean S, Stohler R, Déglon JJ, Livoti S, Waldvogel D, Uehlinger C, et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence.
Drug Alcohol Depend
. 2001 Mar;62(1):97–104.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.